In our disagreement about the settlement between JNJ and DECN, let's keep in mind that in the few weeks since it came down, DECN has lost over half of its share value and JNJ is trading at its historical high.
That probably says more about what happened than anything you or I can say.
Something I'm sure that we already do agree on is the definition of the word "nuisance."
That probably says more about what happened than anything you or I can say.
Something I'm sure that we already do agree on is the definition of the word "nuisance."
Life is as much a merry tavern as it is a sad hotel.
--Tennessee Williams
Recent JNJ News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/22/2026 08:02:41 PM
- Johnson & Johnson’s IMAAVY Demonstrates Durable Disease Control in Myasthenia Gravis • IH Market News • 04/22/2026 12:49:42 PM
- IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG) • PR Newswire (US) • 04/22/2026 12:05:00 PM
- Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference • Business Wire • 04/21/2026 08:22:00 PM
- Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026 • Business Wire • 04/21/2026 11:45:00 AM
- The Infrastructure Play Hiding in Plain Sight Across Cardiac Care • GlobeNewswire Inc. • 04/16/2026 03:00:00 PM
- Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference • Business Wire • 04/15/2026 08:11:00 PM
- Johnson & Johnson Beats Q1 Expectations, Lifts 2026 Outlook • IH Market News • 04/14/2026 12:42:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/14/2026 11:35:25 AM
- Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1% • Business Wire • 04/14/2026 10:21:00 AM
- Johnson & Johnson reports Q1 2026 results, raises 2026 outlook • Business Wire • 04/14/2026 10:20:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/13/2026 03:15:34 PM
- Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision • Business Wire • 04/10/2026 12:00:00 PM
- Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value • InvestorsHub NewsWire • 04/09/2026 01:00:00 PM
- Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value • GlobeNewswire Inc. • 04/09/2026 12:30:00 PM
- Johnson & Johnson introduces VARIPULSE Pro in Europe after CE Mark clearance • IH Market News • 04/07/2026 02:12:35 PM
- Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe • Business Wire • 04/07/2026 12:00:00 PM
- Royalty Pharma signs $500M co-development agreement with J&J • IH Market News • 03/30/2026 12:28:19 PM
- J&J reports one-year ICOTYDE psoriasis trial results show sustained efficacy • IH Market News • 03/30/2026 09:32:48 AM
- ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis • PR Newswire (US) • 03/28/2026 02:00:00 PM
- Nanobiotix Shares Surge After Report of Possible Johnson & Johnson Takeover Interest • IH Market News • 03/25/2026 02:00:48 PM
- FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide • PR Newswire (US) • 03/18/2026 11:49:00 AM
- Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer • PR Newswire (US) • 03/13/2026 04:35:00 PM
